RBD-specific antibody response after two doses of different SARS-CoV-2 vaccines during the mass vaccination campaign in Mongolia
Author:
Batmunkh Burenjargal, Otgonbayar Dashpagma, Shaarii ShatarORCID, Khaidav NansalmaaORCID, Shagdarsuren Oyu-Erdene, Boldbaatar Gantuya, Danzan Nandin-Erdene, Dashtseren Myagmartseren, Unurjargal Tsolmon, Dashtseren Ichinnorov, Dagvasumberel Munkhbaatar, Jagdagsuren Davaalkham, Bayandorj Oyunbileg, Biziya Baasanjargal, Surenjid Seesregdorj, Togoo Khongorzul, Bat-Erdene Ariunzaya, Narmandakh Zolmunkh, Choijilsuren GansukhORCID, Batmunkh Ulziisaikhan, Soodoi Chimidtseren, Boldbaatar Enkh-AmarORCID, Byambatsogt Ganbaatar, Byambaa Otgonjargal, Deleg Zolzaya, Enebish Gerelmaa, Chuluunbaatar Bazardari, Zulmunkh Gereltsetseg, Tsolmon Bilegtsaikhan, Gunchin Batbaatar, Chimeddorj Battogtokh, Dambadarjaa Davaalkham, Sandag TsogtsaikhanORCID
Abstract
The SARS-CoV-2 vaccination campaign began in February 2021 and achieved a high rate of 62.7% of the total population fully vaccinated by August 16, 2021, in Mongolia. We aimed to assess the initial protective antibody production after two doses of a variety of types of SARS-CoV-2 vaccines in the Mongolian pre-vaccine antibody-naïve adult population. This prospective study was conducted from March-April to July-August of 2021. All participants received one of the four government-proposed COVID-19 vaccines including Pfizer/BioNTech (BNT162b2), AstraZeneca (ChAdOx1-S), Sinopharm (BBIBP-CorV), and Sputnik V (Gam-COVID-Vac). Before receiving the first shot, anti-SARS-CoV-2 S-RBD human IgG titers were measured in all participants (n = 1833), and titers were measured 21–28 days after the second shot in a subset of participants (n = 831). We found an overall average protective antibody response of 84.8% (705 of 831 vaccinated) in 21–28 days after two doses of the four types of COVID-19 vaccines. Seropositivity and titer of protective antibodies produced after two shots of vaccine were associated with the vaccine types, age, and residence of vaccinees. Seropositivity rate varied significantly between vaccine types, 80.0% (28 of 35) for AstraZeneca ChAdOx1-S; 97.0% (193 of 199) for Pfizer BNT162b2; 80.7% (474 of 587) for Sinopharm BBIBP-CorV, and 100.0% (10 of 10) for Sputnik V Gam-COVID-Vac, respectively. Immunocompromised vaccinees with increased risk for developing severe COVID-19 disease had received the Pfizer vaccine and demonstrated a high rate of seropositivity. A high geometric mean titer (GMT) was found in vaccinees who received BNT162b2, while vaccinees who received ChAdOx1-S, Sputnik V, and BBIBP-CorV showed a lower GMT. In summary, we observed first stages of the immunization campaign against COVID-19 in Mongolia have been completed successfully, with a high immunogenicity level achieved among the population with an increased risk for developing severe illness.
Publisher
Public Library of Science (PLoS)
Subject
Multidisciplinary
Reference39 articles.
1. Factors Associated with COVID-19 Vaccine Hesitancy in Mongolia: A Web-Based Cross-Sectional Survey.;D Dambadarjaa;International journal of environmental research and public health,2021 2. Attitudes towards Mandatory Occupational Vaccination and Intention to Get COVID-19 Vaccine during the First Pandemic Wave among Mongolian Healthcare Workers;B Turbat;A Cross-Sectional Survey. International Journal of Environmental Research and Public Health,2022 3. Early policy actions and emergency response to the COVID-19 pandemic in Mongolia: experiences and challenges;R Erkhembayar;The Lancet Global Health,2020 4. Health emergency preparedness and response to the COVID-19 pandemic: Lessons learnt from Mongolia;A Dagvadorj;The Lancet Regional Health–Western Pacific,2022 5. A Comparative Analysis of COVID-19 Vaccine Distribution Efforts in India and Mongolia through Data Visualization;L Paridhi;External Student Research Opportunities,2022
|
|